Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'

The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. Beaker In a May 20 research report, ROTH Capital Partners analyst Yasmeen Rahimi reported that The Medicines Company's (MDCO:...

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. In a March 21 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:OTC.MKTS) is "positioned for success" following its e...

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

The study data and their implications are provided in a BTIG report. In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are "as hoped" from Esperion Therapeutics Inc.'s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezet...

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...

Krill oil boom is real

There’s a new type of oil that’s causing a major stir in the markets. This oil boom has nothing to do with crude oil or energy though. But it still has the potential to be just as profitable. I’m talking about krill oil. ...

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...

A technical update on the mini-crash in gold

Let's make one thing clear; nobody I know including myself predicted that Gold would drop from 1690 to 1625 inside of 48 hours this week. That was not in the charts and so I won’t even pretend I was going to see that train coming through the tunnel. With th...

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress

Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. Amarin Corp. (AMRN:NASDAQ) ADR shares are up sharply today after the com...

Is The Other Shoe About To Drop With Fed News?

We've been watching the markets today and over the past few days after the Saudi Arabia attack and are surprised with the real lack of volatility in the US major markets – excluding the incredible move higher, then lower in Oil. The real news appears to be something completely...

An emerging low in gold stocks?

Gold stocks have been in another recent downtrend, which makes sense during a “wave 2″ correction in gold. If we review the Market Vectors ETF Trust Market Vectors Gold Miners ( NYSE: GDX , Stock Forum ) we can see a possible triple bottom formation. This one though loo...
1 2 3 4 5 6 7 8 9 10 ...